Ignite Creation Date:
2024-05-05 @ 4:58 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00358982
Status:
TERMINATED
Last Update Posted:
2015-07-03
First Post:
2006-07-31
Brief Title:
Study of MGCD0103 MG-0103 in Patients With Relapsed or Refractory Hodgkins Lymphoma
Sponsor:
Mirati Therapeutics Inc
Organization:
Mirati Therapeutics Inc
Study Overview
Official Title:
A Phase II Study of MGCD0103 MG-0103 in Patients With Relapsed or Refractory Hodgkins Lymphoma
Status:
TERMINATED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
MGCD0103 is an experimental drug that belongs to a class of drugs known as the histone deacetylase inhibitors which may restore normal control in cancer cells by affecting the genes and proteins that are being made Laboratory tests show that this new investigational anti-cancer drug can slow down the growth of human cancer cells in mice two clinical research studies are currently being performed in humans with cancer and a similar study is being performed in patients with the same disease
The purpose of this study is to find out what effect the experimental drug MGCD0103 has on patients with relapsed and refractory Hodgkins lymphoma
The purpose of this study is to find out what effect the experimental drug MGCD0103 has on patients with relapsed and refractory Hodgkins lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None